| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in investing activities | -13,149 | 43,627 |
| Proceeds from underwritten public offering, net of underwriter discounts and commissions and deferred offering costs | 269,834 | - |
| Proceeds from exercise of stock options | 642 | 6 |
| Payment of deferred offering costs | - | 63 |
| Repurchase of unvested restricted common stock | 1 | 1 |
| Net cash provided by financing activities | 270,475 | -58 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | 194,554 | -1,738 |
| Cash and cash equivalents at beginning of period | 56,910 | - |
| Cash and cash equivalents at end of period | 251,464 | - |
Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. (RAPP)